Acid ceramidase 1 mRNA (ASAH1 mRNA)

Acid ceramidase 1 (ASAH1) mRNA is the transcript encoding the lysosomal enzyme acid ceramidase, which catalyzes the conversion of ceramide into sphingosine and free fatty acids (UniProt: Q13510). This mRNA plays a central role in sphingolipid metabolism, a pathway that regulates the balance between cell death and survival signals (PubMed: 26545382). Genetic mutations that reduce the stability or expression of ASAH1 mRNA lead to the accumulation of ceramide, causing Farber lipogranulomatosis and spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) (PubMed: 24037777). In contrast, the overexpression of ASAH1 mRNA is a hallmark of several cancers, including prostate and melanoma, where it promotes chemoresistance and tumor progression (PubMed: 24121486). As a therapeutic target, ASAH1 mRNA is being explored for knockdown using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to treat malignancies (PubMed: 15621727). Additionally, mRNA replacement therapies and gene therapies are under investigation to restore functional ASAH1 transcripts in patients with inherited deficiency syndromes (PubMed: 30111531). While clinical efforts have historically focused on the protein product, the mRNA represents a high-precision target for emerging genetic medicine platforms.

Other names

N-acylsphingosine amidohydrolase 1 mRNAAC mRNAAcid ceramidase mRNAASAH mRNAACDase mRNA

The primary mechanisms of action for targeting ASAH1 mRNA include antisense-mediated degradation or RNA interference (RNAi) to reduce enzyme production in cancer, and mRNA replacement or gene therapy to restore functional mRNA levels in deficiency diseases like Farber disease (PubMed: 30111531, PubMed: 24121486).